The Board at its meeting held on August 14, 2025 approved audited financial statements for the FY 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and 0.5 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gian Life Care's board approved audited standalone and consolidated results for FY25 (year ended March 31, 2025) on August 14, 2025. Standalone revenue from operations fell sharply to ₹663.10 lacs from ₹1,311.98 lacs in FY24, a drop of about 49%. Standalone net profit collapsed to ₹15.51 lacs (₹0.14 EPS) from ₹429.57 lacs (₹4.16 EPS). On a consolidated basis, the company slipped into a net loss of ₹3.72 lacs (₹0.04 EPS) versus a profit of ₹415.22 lacs last year. Q4 FY25 standalone showed revenue of ₹111.34 lacs and a loss of ₹47.67 lacs. The auditor issued a qualified opinion on both standalone and consolidated results, flagging that IPO proceeds remain unspent on the originally stated objects (a qualification appearing for the sixth consecutive year) and a new qualification about ₹693.86 lacs in cash sitting alongside ₹421.99 lacs of unpaid statutory dues (income tax, PF, ESI, TDS), which the auditor could not physically verify.
This is a negative read for shareholders: revenue and profits have nearly halved, consolidated bottom line turned into a loss, and the auditor has raised a fresh qualification on cash balances against unpaid taxes — a serious governance and liquidity red flag that could weigh on the stock and attract regulatory scrutiny.